AI Takeaway
Viatris (VTRS) reported a sharp deterioration in FY2025 operating results, with revenue declining 3.0% to $14.3B and a massive swing to a $2.66B operating loss, driven by significant non-cash charges, even as operating cash flow remained resilient at $2.32B.
Revenue
$14.3B
-2.98% YoY
EPS (Basic)
$-3.00
-466.04% YoY
Gross Margin
35.1%
-3.09% YoY
Operating Income
$-2.66B
-26467.33% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
Total revenue fell 3.0% year-over-year from $14.74B to $14.30B in FY2025, reflecting ongoing divestitures and portfolio optimization efforts that have reduced the company's top-line base, partially offset by continued generic and branded product sales globally.
Source: Source: 10-K Income Statement
Gross profit declined 10.8% to $5.01B, with gross margin contracting approximately 310 basis points from 38.2% to 35.1%, as cost of revenue rose 1.9% to $9.29B even as revenues fell, indicating rising manufacturing or product mix pressures.
Source: Source: 10-K Income Statement
Operating income swung dramatically from a near-breakeven $10.1M in the prior year to a loss of $2.66B in FY2025, likely reflecting large goodwill impairment or intangible asset write-downs, given that D&A alone was $2.80B and SG&A declined 7.6% to $3.79B.
Source: Source: 10-K Income Statement & Cash Flow Statement
2 more insights available
Upgrade to unlockThe dramatic swing from near-zero operating income to a $2.66B operating loss in FY2025, despite only modest revenue and SG&A changes, strongly suggests large non-cash impairment charges on goodwill or intangible assets. With total assets declining 10.4% to $37.2B, further impairments could continue to weigh on reported earnings and book value.
Source: Source: 10-K Income Statement & Balance Sheet
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $0.57 versus the $0.54 analyst consensus — a +4.8% beat for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $14.3B | $14.74B | -2.98% |
Cost of Revenue | $9.29B | $9.12B | +1.87% |
Gross Profit | $5.01B | $5.62B | -10.85% |
Operating Income | $-2.66B | $10.1M | -26467.33% |
EPS (Basic) | $-3.00 | $-0.53 | -466.04% |
EPS (Diluted) | $-3.00 | $-0.53 | -466.04% |
SG&A Expense | $3.79B | $4.1B | -7.56% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $37.19B | $41.5B | -10.38% |
Current Assets | $9.79B | $9.52B | +2.82% |
Total Liabilities | $22.48B | $22.87B | -1.68% |
Current Liabilities | $7.09B | $5.78B | +22.75% |
Cash & Equivalents | $1.32B | $734.8M | +79.97% |
Long-Term Debt | $12.48B | $14.04B | -11.10% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.32B | $2.3B | +0.56% |
Investing Cash Flow | $-427.7M | $1.8B | -123.75% |
Financing Cash Flow | $-1.29B | $-4.33B | +70.12% |
Share Buybacks | $500.5M | $250M | +100.20% |
D&A | $2.8B | $2.89B | -3.28% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 35.1% | 38.2% | -3.09% |
Operating Margin | -18.6% | 0.1% | -18.69% |
Current Ratio | $1.38 | — | — |
Other companies in Pharmaceuticals
Viatris reported a $2.66B operating loss in FY2025, a dramatic reversal from near-breakeven in the prior year, despite only a 3.0% revenue decline and a 7.6% reduction in SG&A. The most likely explanation is large non-cash goodwill or intangible asset impairment charges, as total assets fell 10.4% to $37.2B while operating cash flow remained healthy at $2.32B.
The key takeaways from Viatris's FY2025 results are: revenue declined 3.0% to $14.3B, gross margin compressed to 35.1% from 38.2%, and a large non-cash operating loss of $2.66B drove EPS to -$3.00. On the positive side, operating cash flow held steady at $2.32B, long-term debt was reduced 11.1% to $12.48B, and cash on hand surged 80% to $1.32B.
Yes, Viatris made meaningful progress on deleveraging in FY2025, reducing long-term debt by 11.1% from $14.04B to $12.48B. The company also increased its cash position by 80% to $1.32B, and financing cash outflows moderated significantly to $1.29B from $4.33B in the prior year.
Viatris's operating cash flow remained resilient at $2.32B in FY2025, essentially flat with the prior year's $2.30B, demonstrating that the large operating loss was primarily driven by non-cash charges such as impairments rather than a deterioration in cash earnings. The company also doubled its share buybacks to $500.5M, reflecting management's confidence in ongoing cash generation.
Key risks highlighted by Viatris's FY2025 financial data include potential further goodwill and intangible asset impairments given the large operating loss, a still-elevated long-term debt load of $12.48B, and a 22.8% surge in current liabilities that narrowed the current ratio to 1.38x. Continued revenue erosion from generic drug pricing pressure and the impact of ongoing divestitures also pose risks to future cash flow generation.